

Company analysis: BASF
Company Analysis: BASF
Data supports a materially improved FY2026 earnings outlook (EBITDA before special items now guided at €7.4–€7.8bn) with unchanged free cash flow guidance (€1.5–€2.3bn), indicating that cash conversion remains the gating factor despite better operating performance. (basf.com) Recent results show YoY EBITDA improvement (Q3 2026 EBITDA before special items €1.6bn; Q2 2026 €2.4bn prelim.) but also highlight working-capital sensitivity (Q2 free cash flow -€0.2bn). (basf.com) In parallel, reported Evonik takeover approaches introduce event risk around capital allocation and potential deal economics. (icis.com) Given these cross-currents and the absence of a confirmed current price in this request, HOLD is the most defensible, strictly data-driven stance until cash conversion and any M&A path become clearer.
Summary
BASF SE is a diversified chemicals group with an integrated “Verbund” production model (shared feedstocks, utilities and intermediates across sites) and a portfolio spanning Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care, and Agricultural Solutions. The core competency is large-scale, asset-intensive chemical manufacturing combined with application know-how and global customer coverage, with earnings highly sensitive to energy/feedstock costs, chemical spreads, and industrial demand. In recent months, the investment narrative has been dominated by (1) a clear operational earnings recovery through 2026, (2) portfolio actions (notably the Coatings transaction completion), and (3) a step-up in full-year guidance. BASF reported Q3 2026 sales of €16.4bn (vs €14.3bn in Q3 2025) and EBITDA before special items of €1.6bn (vs €1.4bn). (basf.com) In July 2026, BASF released preliminary Q2 2026 figures showing sales of €17.2bn (+16% YoY) and EBITDA before special items of €2.4bn, above consensus, while free cash flow was -€0.2bn due to higher working capital tied up from higher raw material prices. (basf.com) The Coatings transaction with Carlyle closed on June 30, 2026; BASF highlighted that the disposal gain is recognized in discontinued operations and flows through net income/EPS. (basf.com) Guidance has been raised twice in 2026. After lifting the EBITDA before special items outlook to €6.9–€7.7bn in July, BASF’s latest outlook (updated Oct 28, 2026) guides to EBITDA before special items of €7.4–€7.8bn for FY2026, while keeping free cash flow guidance at €1.5–€2.3bn. (basf.com) This implies 2026 EBITDA before special items above 2025’s €6.554bn baseline referenced in BASF’s outlook tables. (basf.com) Valuation metrics depend on the listing used; third-party market data sources currently show a mid-teens forward P/E for 2026 and a higher 2027 P/E (reflecting earnings normalization assumptions), while trailing P/E appears higher due to cyclicality and special items/noise. (uk.marketscreener.com) Near-term, the key data-driven debate is whether the earnings recovery (volumes/pricing and spreads) can persist while managing energy/feedstock volatility and working-capital swings; BASF explicitly flags uncertainty around energy and raw materials prices and supply chains in its outlook commentary. (basf.com) Medium-term, execution on cost/efficiency programs and portfolio optimization (including M&A optionality) remains a swing factor; market attention has increased after reports of BASF’s non-binding approach to Evonik and subsequent bid discussions in late Sep–Oct 2026. (icis.com)
Key Takeaways
- FY2026 guidance has been upgraded to EBITDA before special items of €7.4–€7.8bn, with free cash flow still guided at €1.5–€2.3bn (Oct 28, 2026 update). (basf.com)
- Q3 2026 showed YoY improvement: sales €16.4bn (vs €14.3bn) and EBITDA before special items €1.6bn (vs €1.4bn). (basf.com)
- Q2 2026 preliminary results exceeded consensus on EBITDA before special items (€2.4bn vs Vara consensus €2.1bn), but free cash flow was negative (-€0.2bn) due to working-capital effects from higher raw material prices. (basf.com)
- The Coatings transaction with Carlyle closed June 30, 2026; BASF states the disposal gain is recognized in discontinued operations and reflected in net income/EPS. (basf.com)
- Market focus has expanded to capital allocation and potential portfolio moves after reported non-binding takeover approaches toward Evonik (Sep–Oct 2026), which could alter leverage, integration risk, and synergy/cost trajectories. (icis.com)
Action Ideas
Action is supported only for investors who prioritize improving operating momentum and are comfortable underwriting BASF’s updated FY2026 earnings range. The company has raised FY2026 EBITDA before special items guidance to €7.4–€7.8bn while maintaining free cash flow guidance of €1.5–€2.3bn, indicating management confidence in the earnings trajectory despite macro/energy uncertainty. Q3 2026 and Q2 2026 data points show YoY EBITDA improvement and, in Q2, outperformance versus consensus on EBITDA before special items. The investment case is primarily an earnings-recovery and cash normalization case rather than a multiple-expansion case; position sizing should reflect cyclicality and working-capital volatility evidenced by negative Q2 free cash flow.
Horizon: 12 mo.
Appropriate for investors who want exposure to the improved 2026 earnings profile but require clearer evidence of cash conversion and stability through the cycle. BASF’s guidance upgrades improve visibility on EBITDA before special items, yet free cash flow guidance remains unchanged and recent quarters show sensitivity to raw material-driven working capital. A HOLD stance is also consistent with waiting for more clarity on any potential Evonik transaction path and its implications for capital allocation. Maintain exposure while monitoring quarterly cash flow, segment margins, and any formal M&A steps.
Horizon: 6 mo.
Suitable for investors with low tolerance for macro/energy uncertainty and event-driven outcomes. BASF’s own outlook notes that effects on energy and raw materials prices and supply chains cannot be fully assessed, and Q2 2026 already showed cash flow pressure from higher raw material prices. Additionally, reported takeover approaches toward Evonik introduce uncertainty around potential deal pricing, financing, and strategic fit. If an investor’s mandate emphasizes stable cash generation and limited headline risk, reducing exposure can be justified even amid improved EBITDA guidance.
Horizon: 3 mo.
Contrarian Insights
- • Consensus attention often centers on the EBITDA recovery, but the more decision-relevant variable for equity holders over the next quarters may be cash conversion: BASF maintained FY2026 free cash flow guidance (€1.5–€2.3bn) even while raising EBITDA guidance, and Q2 2026 free cash flow was negative due to working-capital tied up from higher raw material prices. (basf.com)
- • The market may treat the Coatings disposal gain as a one-off accounting uplift; however, the completion of the transaction can also be read as a portfolio simplification step that reduces earnings noise from discontinued operations going forward and can reframe capital allocation discussions (including potential M&A). This is not inherently positive or negative, but it can change how investors benchmark underlying profitability and cash generation. (basf.com)
Sources (8)
- https://www.basf.com/global/en/investors/basf-at-a-glance/outlook
- https://www.basf.com/global/en/investors/calendar-and-publications/service-for-shareholders/ir-magazine/2026/3q2026
- https://www.basf.com/global/en/media/news-releases/2026/07/p-26-132
- https://www.basf.com/global/en/media/news-releases/2026/07/p-26-113
- https://www.icis.com/explore/resources/news/2026/09/29/11235380/evonik-rejects-basf-takeover-bid/
- https://uk.marketscreener.com/news/evonik-we-are-not-ready-to-negotiate-basf-s-sweetened-bid-ce785fdbd881f624
- https://uk.marketscreener.com/quote/stock/BASF-SE-6443227/
- https://finance.yahoo.com/quote/BAS.SG/key-statistics/